A. P. Wunder
Impact in
-
- Optical Imaging and Spectroscopy Techniques
- Monoclonal and Polyclonal Antibodies Research
-
- Nanoparticle-Based Drug Delivery
Papers in
-
- Radiopharmaceutical Chemistry and Applications 3
- Monoclonal and Polyclonal Antibodies Research 2
- Co-authors
- H. Sinn (10 shared papers)Ulrich Dirnagl (2 shared papers)Jan Klohs (2 shared papers)G. Stehle (9 shared papers)Dieter Ludwig Heene (7 shared papers)Wolfgang Maier‐Borst (6 shared papers)H. H. Schrenk (6 shared papers)Eckhard A. Friedrich (3 shared papers)
- Journals
- European Journal of Cancer (2 papers)Journal of neurosurgery (1 paper)Neuroscience (1 paper)Current Medicinal Chemistry (1 paper)Journal of Clinical Investigation (1 paper)
- Partner nations
- GermanyUnited States
In The Last Decade
A. P. Wunder
18 papers receiving 379 citations
Peers
Comparison fields: 5 of 79
- Radiology, Nuclear Medicine and Imaging 119
- Biomaterials 74
- Neurology 30
- Hematology 28
- Genetics 25
Countries citing papers authored by A. P. Wunder
This map shows the geographic impact of A. P. Wunder's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by A. P. Wunder with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites A. P. Wunder more than expected).
Fields of papers citing papers by A. P. Wunder
This network shows the impact of papers produced by A. P. Wunder. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by A. P. Wunder. The network helps show where A. P. Wunder may publish in the future.
Co-authors
The 25 scholars most cited alongside A. P. Wunder, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Phase I trial of methotrexate-albumin in a weekly intravenous bolus regimen in cancer patients. Phase I Study Group of the Association for Medical Oncology of the German Cancer Society. | 1999 | 84 |
| 2 | 1997 | 66 | |
| 3 | 2008 | 55 | |
| 4 | 2000 | 42 | |
| 5 | 2005 | 42 | |
| 6 | 2008 | 39 | |
| 7 | 1992 | 23 | |
| 8 | 2005 | 17 | |
| 9 | 2005 | 8 | |
| 10 | 2012 | 6 | |
| 11 | 1995 | 6 | |
| 12 | Altered pharmacokinetic properties of a lipophilically derivatized low-molecular-weight heparin in rats. | 1993 | 4 |
| 13 | 2023 | 4 | |
| 14 | 2003 | 3 | |
| 15 | 2000 | 3 | |
| 16 | 1997 | 2 | |
| 17 | 1999 | 1 | |
| 18 | Nuclear imaging to support anti-inflammatory drug discovery and development. | 2014 | 1 |
| 19 | 1999 | 1 |
About A. P. Wunder
A. P. Wunder is a scholar working on Radiology, Nuclear Medicine and Imaging, Cell Biology, Neurology, Genetics and Hematology, having authored 19 papers that have together received 407 indexed citations. Recurring topics across this work include Radiopharmaceutical Chemistry and Applications (3 papers), Cancer Treatment and Pharmacology (3 papers), Monoclonal and Polyclonal Antibodies Research (2 papers), Rheumatoid Arthritis Research and Therapies (2 papers), Chronic Myeloid Leukemia Treatments (2 papers), Advanced Biosensing Techniques and Applications (2 papers), Chronic Lymphocytic Leukemia Research (2 papers) and Cancer, Hypoxia, and Metabolism (2 papers). The work is most often cited by research in Radiology, Nuclear Medicine and Imaging (119 citations), Biomaterials (74 citations), Neurology (30 citations), Hematology (28 citations) and Genetics (25 citations). A. P. Wunder has collaborated with scholars based in Germany and United States. Frequent co-authors include H. Sinn, Ulrich Dirnagl, Jan Klohs, G. Stehle, Dieter Ludwig Heene, Wolfgang Maier‐Borst, H. H. Schrenk, Eckhard A. Friedrich, Ulf Müller‐Ladner and Rainer Hans Straub. Their work appears in journals such as European Journal of Cancer, Journal of neurosurgery, Neuroscience, Current Medicinal Chemistry and Journal of Clinical Investigation.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.